SARS-CoV-IN-6

SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs[1].

Product Specifications

CAS Number

[2244671-47-2]

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/sars-cov-in-6.html

Smiles

CN1C(N(C)C=C(CNC2=CC=C3N(C[C@H]4C[C@@H]3CN(CC5=CC=CC=C5)C4)C2=O)C1=O)=O

Molecular Formula

C25H29N5O3

Molecular Weight

447.53

References & Citations

[1]Chen Y, et al. Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-) -cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2. Bioorg Med Chem Lett. 2024 Sep 7;113:129950.